Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Net Cash Flow (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Net Cash Flow for 15 consecutive years, with -$6.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 122.63% to -$6.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$216.0 million, a 505.69% decrease, with the full-year FY2024 number at -$142.5 million, down 420.84% from a year prior.
  • Net Cash Flow was -$6.1 million for Q3 2025 at Usana Health Sciences, up from -$30.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $37.0 million in Q4 2022 to a low of -$176.4 million in Q4 2024.
  • A 5-year average of -$14.4 million and a median of $1.7 million in 2024 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: soared 1542.61% in 2023, then tumbled 1011.32% in 2024.
  • Usana Health Sciences' Net Cash Flow stood at -$53.9 million in 2021, then surged by 168.7% to $37.0 million in 2022, then crashed by 47.72% to $19.4 million in 2023, then crashed by 1011.32% to -$176.4 million in 2024, then surged by 96.52% to -$6.1 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Net Cash Flow are -$6.1 million (Q3 2025), -$30.6 million (Q2 2025), and -$2.9 million (Q1 2025).